Semaglutide is a synthetic version of GLP-1, a hormone your gut naturally releases after eating, and it has become one of the most studied drugs of the past decade. Approved under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight management), it consistently produces weight loss in the range of 15% of body weight in clinical trials while also lowering blood sugar and reducing cardiovascular risk. The breadth of evidence behind it is unusual for any single medication, spanning diabetes management, heart disease, kidney protection, liver disease, and even early-stage research into alcohol cravings.
How Semaglutide Works
Semaglutide mimics a hormone called GLP-1 that your body produces in the intestines after meals. Natural GLP-1 breaks down in minutes, but semaglutide is engineered to last about a week in the bloodstream, which is why the injectable version is dosed once weekly. It acts on GLP-1 receptors throughout the body, but its effects on the brain are central to how it suppresses appetite.
In animal studies, semaglutide reaches several brain regions without fully crossing the blood-brain barrier. Instead, it interacts with the brain through areas near the ventricles that lack the usual barrier, activating neurons across at least ten brain regions involved in food intake, reward processing, and energy expenditure.1PubMed Central. Semaglutide lowers body weight in rodents via distributed neural pathways More recent work has mapped these pathways in finer detail, identifying specific brainstem-to-hypothalamus circuits that suppress the drive to eat palatable food while separately regulating metabolism and fat-burning.2bioRxiv. Semaglutide engages distinct brainstem-to-hypothalamus circuits to suppress motivated feeding and regulate ketogenesis and energy expenditure
One of the more intriguing findings is what semaglutide does to the brain’s reward system. In a study measuring dopamine-neuron activity, semaglutide reduced the number of sugar rewards animals collected yet actually increased dopamine signaling in the brain’s reward center during the moments of collection.3Neuroscience Applied. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling The implication is that you want less food, but the food you do eat may feel more satisfying. This could help explain why many users report a quieter, less intrusive relationship with food rather than the deprivation-driven experience typical of calorie-restriction diets.
Below the neck, semaglutide slows gastric emptying, meaning food stays in your stomach longer after a meal. In one study, the time for half a meal to leave the stomach was about 170 minutes with semaglutide compared to 118 minutes with placebo, and at four hours, semaglutide users still retained over a third of the meal in their stomachs while placebo users had none left.4PubMed. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity This slowed digestion contributes to feeling full longer after eating, though it also connects to some of the drug’s side effects, which we’ll get to later. Semaglutide also boosts insulin release in a glucose-dependent way, dials down the liver’s sugar production, and suppresses glucagon, all of which help keep blood sugar in check.
Weight Loss in Clinical Trials
The weight-loss numbers from semaglutide trials are striking by the standards of obesity pharmacotherapy. In the landmark STEP 1 trial, adults with overweight or obesity who received the 2.4 mg weekly dose lost an average of about 15% of their body weight over 68 weeks, compared with roughly 2.4% in the placebo group. More than two-thirds of semaglutide users lost at least 10% of their starting weight, and about half lost 15% or more.5PubMed. Once-Weekly Semaglutide in Adults with Overweight or Obesity Across multiple STEP trials, average losses ranged from about 15% to 17% at 68 weeks in people without type 2 diabetes, and those results held up at two years in the STEP 5 extension.6PubMed Central. Semaglutide for the treatment of overweight and obesity: A review
The SELECT trial, designed primarily to study cardiovascular outcomes, provided the longest look at weight trajectories. Weight loss continued through about week 65 and then held steady through week 208, roughly four years. People still on the drug at that point had lost about 10% from their starting weight, and when the analysis counted only the time people were actually taking their medication, the loss was closer to 12%.7Nature Medicine. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial The plateau suggests the drug reaches a steady state rather than producing indefinite loss, but the fact that the weight stayed off for years on continued treatment is clinically meaningful.
Blood Sugar Control
Semaglutide was originally developed for type 2 diabetes, and the evidence for blood sugar lowering is mature. Across nine phase 3 SUSTAIN trials, semaglutide reduced HbA1c (a marker of average blood sugar over roughly three months) by about 1.5 percentage points, with weight reductions of approximately 4.5 kilograms, comparable to another GLP-1 drug, dulaglutide, for blood sugar lowering.8PubMed Central. Semaglutide for the Treatment of Type 2 Diabetes Mellitus At the higher dose (1.0 mg), reductions were even more pronounced. In one trial of patients already on basal insulin, semaglutide at the higher dose brought average HbA1c down to about 6.5%, compared with 8.3% in the placebo group.9The Journal of Clinical Endocrinology & Metabolism. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial The combination of significant blood sugar control and weight loss makes semaglutide an attractive option for people with type 2 diabetes, since many older diabetes medications cause weight gain.
Cardiovascular and Kidney Benefits
Perhaps the most consequential finding beyond weight and blood sugar is that semaglutide reduces the risk of heart attacks, strokes, and cardiovascular death. The SELECT trial enrolled about 17,600 people who were overweight or obese and already had cardiovascular disease but did not have diabetes. Major cardiovascular events occurred in about 6.5% of the semaglutide group versus 8% of the placebo group, a 20% relative risk reduction.10PubMed. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes This was a meaningful shift because it demonstrated cardiovascular protection from semaglutide in people without diabetes, expanding the drug’s clinical relevance well beyond blood sugar management.
Kidney protection has followed a similar trajectory. In patients with type 2 diabetes and chronic kidney disease, semaglutide reduced the risk of major kidney events by about 24% compared with placebo, while also slowing the decline in kidney function over time. Cardiovascular death was also reduced by roughly 29% in this population.11PubMed. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes These results led the FDA to approve semaglutide (as Ozempic) specifically for reducing the risk of worsening kidney disease and kidney failure in adults with type 2 diabetes and chronic kidney disease, making it the first GLP-1 drug to carry this indication.12JAMA. FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression Whether these benefits come from weight loss itself, the drug’s direct effects on inflammation and blood vessels, or some combination is an active area of study.
Side Effects and Safety Concerns
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are most frequent during dose escalation and tend to improve as the body adjusts, which is why the standard prescribing protocol involves gradual dose increases over several months. Most people tolerate these symptoms well enough to continue treatment, but they are the primary reason some users discontinue.
More serious but less common concerns include pancreatitis and gallbladder disease. Pharmacovigilance data have flagged a notable signal for pancreatitis with semaglutide, and one analysis found roughly a nine-fold increased risk in non-diabetic people using GLP-1 drugs compared with those taking a different weight-loss medication.13PubMed Central. Acute Pancreatitis Likely Due to Semaglutide Case reports have also documented acute biliary pancreatitis after dose escalation, particularly in patients who already had gallstones, suggesting that rapid weight loss may destabilize existing gallbladder stones.14PubMed Central. Case Report: Acute biliary pancreatitis after semaglutide dose escalation in an adolescent with obesity and cholelithiasis
On the gallbladder front specifically, a meta-analysis of randomized trials found that higher doses of subcutaneous semaglutide (1.0 mg and above) were associated with a statistically significant increase in gallbladder and biliary disease, with about a 58% higher relative risk.15JAMA Internal Medicine. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases This is not unique to semaglutide; rapid weight loss by any means, including bariatric surgery, carries gallstone risk. But it is worth being aware of, especially if you have a history of gallbladder problems.
What Happens When You Stop
This is the question that looms over every semaglutide success story. The STEP 1 trial included a follow-up period after treatment ended, and the results were sobering: participants who stopped semaglutide regained about two-thirds of the weight they had lost within a year. On average, they had lost weight through week 68, then regained about 12 percentage points of that loss by week 120 after stopping, ending up with a net loss of roughly 5.6% from their starting weight. Most of the cardiometabolic improvements, such as improvements in blood pressure and cholesterol markers, also drifted back toward baseline.16PubMed Central. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
A broader meta-analysis across multiple GLP-1 drug trials found that people with obesity regained an average of about 5.6 kilograms after stopping, with longer follow-up periods producing more regain. Semaglutide users actually experienced more rebound than liraglutide users (about 8 kg versus 4 kg), likely because they had lost more in the first place. Systolic blood pressure, waist circumference, and fasting glucose also deteriorated after discontinuation.17The Lancet Diabetes & Endocrinology. Metabolic and cardiovascular rebound following the discontinuation of GLP-1 receptor agonists: a systematic review and meta-analysis The clinical takeaway is clear: for most people, semaglutide requires ongoing use to maintain its benefits, much like blood pressure or cholesterol medications. This has significant implications for cost, access, and how the medical system approaches obesity as a condition.
Lean Mass and Body Composition
A persistent concern is that weight lost on semaglutide may include too much muscle and other lean tissue rather than just fat. The data here are mixed and depend heavily on how measurements are done. Across clinical trials, reductions in lean mass have ranged from nearly zero to as much as 40% of total weight lost, though larger trials tend to show meaningful lean-mass decreases.18PubMed. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials That wide range partly reflects differences in measurement techniques and study populations.
There is a useful nuance buried in the numbers, though. Even when absolute lean mass drops, the proportion of lean mass relative to total body mass tends to go up, because fat is being lost at a faster rate. In other words, your body composition may actually improve in terms of the ratio of muscle to fat, even if total lean mass falls somewhat.19PubMed. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials Still, for people losing large amounts of weight, resistance exercise and adequate protein intake during treatment are widely recommended to help preserve muscle, and some trials have found that lean-mass loss can range between 15% and 60% of total weight lost depending on how actively these strategies are pursued.20PubMed. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies
How Semaglutide Compares to Tirzepatide
Tirzepatide (sold as Mounjaro and Zepbound) is the most direct competitor, and the head-to-head data favor it for weight loss. In a large real-world study, patients on tirzepatide were nearly twice as likely to lose at least 5% of their body weight and more than three times as likely to lose 15% or more. At 12 months, the weight-loss gap was about 7 percentage points in tirzepatide’s favor.21JAMA Internal Medicine. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity A meta-analysis pooling both clinical trials and real-world data confirmed that tirzepatide produced about 4 to 6.5 kilograms more weight loss than semaglutide, with the advantage growing at higher tirzepatide doses and longer treatment durations.22PubMed Central. Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data
The difference likely comes down to mechanism: tirzepatide activates two receptors (GLP-1 and GIP) rather than just one. That said, semaglutide has a much longer track record, a broader evidence base for cardiovascular and kidney outcomes, and more established real-world persistence data. In one large U.S. database analysis, roughly 67% of semaglutide users were still on the drug at one year, substantially higher than other once-weekly or daily GLP-1 drugs.23PubMed Central. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting Tirzepatide’s long-term cardiovascular outcome data are still being collected, so the choice between the two drugs involves weighing the weight-loss edge of tirzepatide against semaglutide’s deeper evidence base in outcomes that go beyond the scale.
Injectable Versus Oral Formulations
Semaglutide is available as both a once-weekly subcutaneous injection and a daily oral tablet (brand name Rybelsus, approved for type 2 diabetes). The oral version was a pharmacological achievement because peptide drugs typically get destroyed in the stomach. Semaglutide tablets are co-formulated with a compound called SNAC that helps the drug absorb through the stomach lining. Because semaglutide has a long half-life, once-daily dosing achieves stable blood levels despite the low bioavailability of each individual tablet.24PubMed Central. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
The oral form does require specific dosing instructions: you take it on an empty stomach with no more than four ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications. Food and larger volumes of water interfere with absorption. The injectable version has none of these restrictions and delivers more consistent drug levels. For weight management at the higher 2.4 mg dose, only the injectable form is currently approved, so the oral tablet is primarily relevant for diabetes management at present.
Emerging Uses Beyond Weight and Diabetes
The research pipeline for semaglutide is expanding into conditions you might not immediately associate with a diabetes or weight-loss drug. Fatty liver disease is among the most promising. A meta-analysis of three randomized trials found that semaglutide roughly tripled the odds of resolving the inflammatory form of fatty liver disease and significantly improved measures of liver inflammation and cell damage, though it did not improve liver fibrosis (scarring).25PubMed Central. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease A larger and more recent meta-analysis confirmed the same pattern: improvement in fat buildup, inflammation, and ballooning of liver cells, but no clear benefit for fibrosis.26The Journal of Clinical Endocrinology & Metabolism. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis Since fibrosis is the stage most associated with liver failure, this is both encouraging and incomplete.
Alcohol use disorder is another frontier. A small randomized trial found that low-dose semaglutide reduced the amount of alcohol people consumed in a lab setting, cut the number of drinks per drinking day, and lowered weekly alcohol cravings, all with medium to large effect sizes. It also predicted greater reductions in heavy drinking over time compared with placebo.27JAMA Network. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial This is early-stage evidence from a single trial, but it aligns with the broader observation that GLP-1 drugs interact with the brain’s reward pathways in ways that extend beyond food.
Anesthesia and Surgery Considerations
The same gastric-emptying delay that helps you feel full for longer creates a genuine safety concern if you need surgery or a procedure requiring sedation. Standard pre-operative fasting guidelines assume a normal rate of stomach emptying, but semaglutide users can retain significant food in their stomachs even after following those guidelines. In one documented case, food residue was discovered in the stomach of a patient who had followed all standard fasting instructions, forcing cancellation of the procedure.28PubMed Central. Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying
A larger study found that GLP-1 drug use was associated with roughly two and a half times the risk of having retained stomach contents before anesthesia after adjustment for other factors.29JAMA Surgery. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia The concern is pulmonary aspiration: if stomach contents come up during anesthesia, they can enter the lungs, a potentially life-threatening complication. Many anesthesia departments now ask about GLP-1 drug use during pre-operative screening, and some recommend holding the drug for one to three weeks before elective procedures, or performing a pre-procedure ultrasound of the stomach to check for retained food.30PubMed Central. Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia If you are on semaglutide and have an upcoming procedure, this is a conversation to initiate with your surgical team rather than assume they will ask.
Real-World Adherence and Access
Clinical trials select motivated participants who get free medication and regular follow-up. Real-world results are messier. In one outpatient study tracking semaglutide users for two years, roughly 42% discontinued during that period.31Obesity and Endocrinology. Semaglutide in a real-world outpatient setting: discontinuation patterns and weight maintenance In a large academic obesity clinic, the median time patients stayed on treatment was about 11 months, with most semaglutide users eventually escalating to at least the 1 mg dose, and about a quarter reaching the weight-management dose of 2.4 mg.32PubMed Central. Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
Cost is the elephant in the room. At U.S. list prices, semaglutide runs over a thousand dollars per month without insurance coverage, and coverage remains inconsistent. Medicaid, Medicare, and many commercial plans have restrictions on covering weight-management drugs, and drug shortages driven by massive demand have further complicated access.33PubMed. Challenges in the management of obesity The tension is real: the drug appears to be cost-effective over a lifetime, but the up-front expense of treating a large portion of the population is staggering.34PubMed Central. Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US Compounded formulations have emerged as a cheaper alternative, though they come with their own safety and quality-control uncertainties. Given that the evidence points toward lifelong treatment for sustained benefit, the access question is not a short-term inconvenience but a fundamental barrier that shapes who actually benefits from the drug and who does not.35PubMed. Challenges in the management of obesity
Pregnancy, Breastfeeding, and Other Special Populations
Semaglutide carries a pregnancy-related warning. Current evidence is insufficient to support routine use during pregnancy or the postpartum period, and guidelines recommend discontinuing the drug at least two months before a planned conception due to its long half-life.36PubMed Central. Impact of GLP-1 and GLP-1/GIP receptor agonists before, during, and after pregnancy: a narrative review Animal studies have shown adverse developmental effects, and the human data are simply too thin to know whether those risks translate to people.
For breastfeeding, the picture is somewhat more reassuring. A pharmacokinetic study found that semaglutide was not detectable in human breast milk samples at all. Even using worst-case calculations that assumed the drug was present at the lowest measurable concentration, the estimated dose an infant would receive was about 1.3% of the maternal dose, far below the standard 10% safety threshold used in lactation pharmacology.37PubMed Central. Subcutaneous Semaglutide during Breastfeeding: Infant Safety Regarding Drug Transfer into Human Milk That said, open questions remain about whether the drug could affect maternal nutritional status or breast milk composition during a time of high caloric demand, so this remains a conversation to have with a prescriber rather than a blanket green light.